



Patent Application
Attorney Docket No. PC10032C

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 9th day of December, 2004.

By

Kelly A. Smith
(Signature of person mailing)

Kelly A. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael P. DeNinno, et al. :

APPLICATION NO.: 10/607,640 : Examiner: D. Margaret Seaman

FILING DATE: June 27, 2003 : Group Art Unit: 1625

TITLE: 4-CARBOXYAMINO-2-SUBSTITUTED- :
1, 2, 3, 4,-TETRAHYDROQUINOLINES

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

The owner, Pfizer Inc., of 100 percent interest in the instant patent application, hereby makes the following disclaimer.

The above-identified application has been rejected for obviousness-type double patenting over commonly owned US patent 6,586,448 of which the instant application was filed as a divisional. Any patent issuing on the instant application will accordingly expire on the same date as the parent, September 7, 2019 i.e., twenty years from the earliest nonprovisional filing date for both applications (September 7, 1999).

The owner hereby agrees that any patent granted on the instant application shall be enforceable only for and during the period that it and US 6,586,448 are and remain commonly owned. Any patent granted on the instant application shall cease to be enforceable at the time that common ownership ceases, although US 6,586,448 shall remain in force and be enforceable for any remainder of its statutory term as defined in 35 USC 154 to 156 and 173. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

12/15/2004 RNRB11 00000022 161445 10607640

02 FC:1814 130.00 DA



The undersigned is an attorney of record.

Please charge the \$110.00 fee under 37 CFR 1.20(d) to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this sheet are enclosed.

Date: 12/9/04

Respectfully submitted,

A. Dean Olson
Attorney for Applicant(s)
Reg. No. 31,185

Pfizer Inc.
Patent Department, Box 519
Eastern Point Road
Groton, CT 06340
(860) 441-4904